Zoetis Investors Sue Over Hidden Librela Safety Risk and Sales Collapse

Zoetis told investors its dog pain drug Librela was a growth engine. The FDA was simultaneously logging thousands of adverse event reports, including seizures, paralysis, and deaths. When the truth caught up with the stock price, it happened four separate times over fifteen months, and the last drop alone wiped out more than a fifth of the company’s value in a single day.

The City of Ann Arbor Retiree Health Care Benefit Plan & Trust filed a securities fraud class action against Zoetis Inc. and several of its top executives on May 27, 2026, in the U.S. District Court for the Southern District of New York. The lawsuit, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis, Inc., No. 26-cv-04401, alleges the company concealed weakening demand for its flagship products while making statements that misled the market about its growth trajectory. At least four major law firms have since issued investor notices, with the lead plaintiff deadline set for July 27, 2026.

Zoetis Securities Fraud Lawsuit Timeline and Updates

May 2023 — Librela Launches in the United States

The FDA approved Librela, the brand name for bedinvetmab, a monoclonal antibody injection designed to manage osteoarthritis pain in dogs. Librela had already launched in Europe in 2020 and built rapid market penetration there before reaching American veterinary clinics. Zoetis marketed the drug as a breakthrough treatment, noting that of the nearly four in ten dogs suffering from osteoarthritis pain, only about a third actually received treatment, framing Librela as an opportunity to capture an underserved market.

April 2024 — Adverse Event Reports Begin Accumulating

The FDA’s Center for Veterinary Medicine had logged 3,674 adverse event reports associated with Librela by April 18, 2024. These reports, submitted by veterinarians and pet owners, documented a range of symptoms including ataxia, seizures, paresis, recumbency, urinary incontinence, and in some cases, death, including euthanasia.

This is the underlying safety signal that would eventually collide with Zoetis’s public growth narrative. The reports kept accumulating throughout 2024, building toward a regulatory response that the lawsuit alleges Zoetis failed to adequately disclose to investors as a material business risk.

January 14, 2025 — The Class Period Begins

The securities fraud complaint identifies January 14, 2025 as the start of the Class Period, the window during which Zoetis and its executives allegedly made false or misleading statements about the company’s business prospects. Plaintiffs allege that throughout this period, the company failed to disclose three specific deteriorating conditions: weakening veterinarian prescription growth for Librela as clinicians grew more cautious following FDA safety warnings, Simparica Trio losing significant market share to a lower-priced competing parasiticide with broader approved use, and Apoquel and Cytopoint losing substantial dermatology market share to a newly launched competing treatment.

December 2024 — The FDA Sends an Open Letter to Veterinarians

The FDA’s Center for Veterinary Medicine issued a “Dear Veterinarian” letter in December 2024, alerting practitioners to safety signals identified during post-marketing surveillance of Librela. The agency’s analysis identified 18 distinct safety signals associated with the drug, spanning neurological events, urinary problems, and musculoskeletal disorders. The FDA noted a disproportionately elevated reporting rate of lameness in dogs receiving the treatment.

Zoetis responded publicly with a statement standing firmly behind the drug. “We continue to have the utmost confidence in the safety and efficacy of Librela,” the company said, noting that with more than 21 million doses distributed globally, no individual adverse event was being reported at a rate higher than what the European Medicines Agency classifies as rare. Global Chief Medical Officer Richard Goldstein added that Zoetis was “watching the reports closely and taking all new information seriously,” while maintaining that the drug’s existing contraindications, not for use in pregnant or lactating dogs or in puppies, remained unchanged.

February 4, 2025 — Zoetis Updates the Librela Label

Roughly six weeks after the FDA’s open letter, Zoetis announced changes to the Librela label. The updated label added a Post-Approval Experience section listing adverse events in order of decreasing frequency across neurological, general, urinary, gastrointestinal, and musculoskeletal categories. It also added a full-page client information sheet for pet owners, explaining what to expect from treatment and what side effects to watch for, along with instructions for reporting adverse events to both Zoetis and the FDA.

Notably, the FDA’s Center for Veterinary Medicine does not currently have the legal authority to mandate safety-related labeling changes for animal drugs the way it can for some human pharmaceuticals. The label update came through Zoetis’s own decision to act on the FDA’s recommendation, not through a regulatory mandate.

August 5, 2025 — First Disclosure: Stock Falls Nearly 4%

Zoetis released its second quarter 2025 financial results, which the lawsuit alleges revealed weakening demand trends within the company’s companion animal portfolio for the first time publicly. On this news, Zoetis stock fell nearly 4 percent.

Here is where it gets complicated for Zoetis’s public messaging up to that point. The company had continued expressing confidence in Librela’s safety and market position even as the FDA’s adverse event database grew and competitive pressure mounted in other product lines. The August disclosure marked the first crack in that narrative becoming visible to the market.

November 4, 2025 — Second Disclosure: Stock Falls Nearly 14%

Zoetis released third quarter 2025 financial results, allegedly disclosing continued weakness in Librela sales alongside increased competitive pressure in both dermatology and parasiticides. The market’s reaction was significantly sharper this time. Zoetis stock fell nearly 14 percent on the news, a far larger single-day decline than the August disclosure had produced.

The pattern is familiar in securities fraud litigation: each successive disclosure event that surprises the market, despite a company’s prior reassuring statements, builds the plaintiffs’ argument that the company knew more than it said, for longer than it should have stayed silent.

February 12, 2026 — Third Disclosure: Guidance Reflects Further Slowing Growth

Zoetis released its fourth quarter and full year 2025 financial results, providing 2026 guidance that the complaint says reflected further slowing growth. The company acknowledged increasing competitive pressures in both parasiticides and dermatology directly in this release. According to the complaint, Zoetis stock price fell further on this news as well, continuing the pattern of successive negative surprises.

May 6–7, 2026 — Fourth Disclosure: Stock Falls More Than 21% in a Single Day

Zoetis reported first quarter 2026 financial results on May 7, 2026, allegedly disclosing slowing overall revenue growth, declining companion animal sales performance, and worsening results across both the dermatology and parasiticides franchises as competition continued to intensify. The market’s reaction this time was severe. Zoetis stock price fell more than 21 percent on the news, by far the largest single-day decline across the entire alleged disclosure sequence, and the event that effectively closed the Class Period on May 6, 2026.

May 27, 2026 — Lead Plaintiff Files Suit

Labaton Keller Sucharow LLP filed the securities class action on behalf of the City of Ann Arbor Retiree Health Care Benefit Plan & Trust, a public pension fund, naming Zoetis and certain top executives as defendants. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, the core legal framework underlying most stock-drop securities fraud litigation in federal court.

June 2026 — Multiple Firms Issue Investor Notices

Through June 2026, several additional securities litigation firms, including Robbins Geller Rudman & Dowd, Kessler Topaz Meltzer & Check, and others, issued public investor alerts encouraging Zoetis shareholders with substantial losses to consider seeking lead plaintiff status before the deadline. This flurry of parallel notices is standard practice in major securities class actions, as competing plaintiffs’ firms position themselves to potentially represent the eventual lead plaintiff and direct the litigation.

What the Lawsuit Actually Alleges

This is the core allegation across the entire complaint: Zoetis executives knew, or should have known, that three of the company’s most important product franchises were losing momentum for specific, identifiable reasons, and chose to keep presenting a more optimistic growth picture to investors than the underlying business reality supported.

The Librela allegation centers on a direct causal chain: FDA safety warnings led to more cautious prescribing behavior among veterinarians, which led to weaker sales growth, which Zoetis allegedly didn’t adequately flag to investors as a structural headwind rather than a temporary blip. The Simparica Trio allegation describes straightforward competitive displacement: a lower-priced parasiticide with broader approved indications captured share in a market that was simultaneously slowing overall, a double pressure on revenue that the complaint says wasn’t properly disclosed. The Apoquel and Cytopoint allegation follows the same competitive displacement pattern in the dermatology category, where a newly launched competing treatment ate into market share Zoetis had previously dominated.

Why the FDA Safety Signal Matters So Much to This Case

Securities fraud cases built around safety-related product risk often hinge on timing: when did the company know about a problem serious enough to affect financial results, and did it disclose that risk to investors before or after the market found out through other channels?

The timeline here is specific and traceable. The FDA’s adverse event database had already logged thousands of reports by April 2024. The FDA’s formal “Dear Veterinarian” letter went out in December 2024. Zoetis updated its product label in February 2025, just before the Class Period’s January 14, 2025 start date. Yet the complaint alleges the company continued making statements throughout 2025 that didn’t adequately capture how much that safety signal was actually affecting prescription behavior and sales, only acknowledging the real scope of the impact through the staggered series of quarterly disclosures that followed.

Zoetis’s public posture throughout this period remained consistently confident. The company repeatedly emphasized that, measured against the European Medicines Agency’s rarity thresholds, no individual adverse event was occurring at a rate higher than “rare.” That statistical framing, while potentially accurate on its own terms, is exactly the kind of statement plaintiffs in securities cases often argue obscures the more immediate business question: not whether an event is statistically rare across millions of doses, but whether veterinarians and pet owners were becoming meaningfully more hesitant to prescribe and administer the drug regardless of the underlying statistical rarity.

The European Antitrust Investigation Adds Another Layer

Separate from the U.S. securities litigation, the European Commission has opened an investigation into potential anticompetitive conduct by Zoetis related to Librela. While that investigation operates under entirely different legal authority and addresses a different question, whether Zoetis used its market position improperly rather than whether it misled investors, its existence reflects how many simultaneous pressure points converged on the same product during the same period: safety concerns, competitive disclosure obligations, and now antitrust scrutiny, all centered on a drug that Zoetis had positioned as a major growth driver.

How Stock-Drop Securities Cases Like This One Typically Proceed

Federal securities fraud class actions follow a fairly standardized procedural path once filed, governed largely by the Private Securities Litigation Reform Act of 1995. Any investor who purchased or acquired Zoetis securities during the Class Period can seek appointment as lead plaintiff, but courts generally favor whichever movant has the largest financial stake in the case and can adequately represent the broader class’s interests.

An investor’s ability to eventually share in any recovery from this case does not depend on serving as lead plaintiff. Absent class members, those who don’t actively seek a leadership role, remain eligible to benefit from any eventual settlement or judgment simply by having purchased Zoetis securities during the Class Period, provided they don’t opt out of the class.

What a Settlement or Judgment Might Eventually Look Like

It’s too early in this litigation to estimate a specific settlement figure, since no motion to dismiss has been resolved and no damages model has been litigated. Securities fraud settlements are typically calculated based on the aggregate trading losses suffered by class members who purchased shares during the Class Period and held them through the corrective disclosures, a complex damages model that accounts for how much of each stock decline is attributable to the alleged fraud versus general market or industry-wide factors unrelated to Zoetis’s specific conduct.

Given that the final, largest disclosure alone wiped out more than 21 percent of Zoetis’s stock value in a single trading day, and that the company has a substantial market capitalization as one of the world’s largest standalone animal health companies, the aggregate trading losses across the 16-month Class Period could be financially significant if the case proceeds toward a negotiated resolution or an adverse jury verdict.

What This Lawsuit Teaches Investors

Most retail investors who held Zoetis stock through 2025 likely experienced this as a series of disappointing earnings reports, not as a coordinated pattern worth scrutinizing for fraud. That’s precisely the dynamic securities class actions exist to address: individual investors rarely have the resources or visibility to connect four separate disclosure events, spread across fifteen months, into a single coherent narrative about what a company allegedly knew and when it chose to share that information.

The pattern here is one worth understanding regardless of how this specific case resolves. A company facing a known regulatory safety signal, like the FDA’s Librela adverse event reports, faces a genuine disclosure tension: how much of an emerging risk needs to be flagged to investors as material before its full financial impact is fully quantifiable? Companies that wait too long to make that determination, allowing the market to absorb the bad news through a series of escalating quarterly surprises rather than a single clear disclosure, are the companies that most often end up facing exactly this kind of litigation.

For pet owners specifically, this case also surfaces a separate, important reminder buried inside the financial story: any medication’s safety profile can change meaningfully after approval, once it’s actually used across millions of real-world doses rather than a controlled clinical trial population. Discussing adverse event reports directly with a veterinarian, rather than relying solely on a manufacturer’s public safety statements, remains the most reliable way to make an informed decision about ongoing treatment.

Readers tracking how regulatory safety signals translate into corporate financial and legal exposure should also follow the Bayer Roundup settlement, which similarly involves a years-long gap between when a safety risk was first identified and when its full financial consequences were resolved through litigation, and the social media addiction lawsuit settlement, which illustrates how disclosure and accountability questions play out across an entirely different industry facing similar scrutiny over what companies knew and when they acted on it.

Read These

• Social media addiction lawsuit settlement
• New Jersey v Amazon lawsuit
• Bayer Roundup settlement
• Music publishers v Anthropic lawsuit
• Reddit v Anthropic lawsuit